Datamonitor's Optimizing Brand Lifecycle Management

With growing cost-containment pressures and scrutiny of pharmaceutical industry actions in reaction to patent expiry, lifecycle management requires early consideration, a thorough understanding of each market, and strategic planning involving many different functions within a company. Early planning leaves a company with a range of strategies to choose from.

Datamonitor's new special report Optimizing Brand Lifecycle Management: Winning Strategies to Maximize Revenue in the Face of Growing Generic Competition analyzes the evolving drug life cycles and the strategies that can be used to maximize profitability before as well as after patent expiry. The report provides additional analysis of critical considerations for optimal drug lifecycle management and is supported by case study analysis of recent strategies employed by biopharmaceutical companies.

Click here to view the 10-page executive summary of this report.

This report provides:

• A review of the key reasons why lifecycle management is important now
• Analysis on the various lifecycle management strategies employed for the early phases of product lifecycle and what questions brand teams need to be asking in order to select the right approach
• Case study analysis showing how reformulated products satisfying unmet need have the best chance of success and the impact different lifecycle management strategies can have on brand sales, including the factors that govern their success/failure
• A breakdown of the key considerations the pahrmaceutical industry must be aware of when devising lifecycle management strategies
• A PowerPoint executive presentation detailing an effective way to communicate Datamonitor’s key insight to colleagues

Optimizing Brand Lifecycle Management: Winning Strategies to Maximize Revenue in the Face of Growing Generic Competition will help you examine the strategies used by the pharmaceutical industry to optimize revenues during the lifecycle of a drug. Although many strategies are available not all are suitable for all drugs. The choice depends on product characteristics, the market and the phase of the lifecycle.

The report will be delivered as a PDF via e-mail. Orders must be paid in full before shipment. All sales are final; no returns or refunds are permitted with this product. For more information, please call 877/437-4276 or e-mail account manager Maureen Croce at mcroce@hcpro.com.

Click here to view the 10-page executive summary of this report.

• Reports

• Other Life Sciences Products